Company Ayala Pharmaceuticals, Inc.

Equities

ADXS

US0076244062

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Chiffre d''affaires - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 18:27:45 24/06/2024 BST			5-day change	1st Jan Change
0.171 ^USD	-34.86%		-34.86%	-74.36%

04-16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.

Number of employees: 21

Managers	Title	Age	Since
Ken Berlin CEO	Chief Executive Officer	59	31/03/18
Roy Golan DFI	Director of Finance/CFO	50	18/10/23
Shmuel Tuvia CTO	Chief Tech/Sci/R&D Officer	-	30/04/22
Carmit Nadri-Shay LAW	General Counsel	-	31/12/17
Irit Klipper-Avni HRO	Human Resources Officer	-	31/12/18
Dana Gelbaum PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
David Sidransky CHM	Chairman	64	31/10/17
Roni Appel BRD	Director/Board Member	57	31/10/04
Murray Goldberg BRD	Director/Board Member	79	30/11/17
Robert Spiegel BRD	Director/Board Member	73	30/11/17
Pini Orbach BRD	Director/Board Member	-	18/10/23
Ken Berlin CEO	Chief Executive Officer	59	31/03/18
Vered Bisker-Leib BRD	Director/Board Member	53	31/07/20
Yuval Cabilly BRD	Director/Board Member	44	18/10/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	42,672,852	42,632,797 ( 99.91 %)	39,452 ( 0.0925 %)	99.91 %

Name	Equities	%	Valuation
Israel Biotech Fund 7.410 %	3,159,142	7.410 %	808 740 $
aMoon Ventures Y Sh Ltd. 1.315 %	560,602	1.315 %	143 514 $
HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD 0.9465 %	403,523	0.9465 %	103 302 $
Redmile Group LLC 0.2898 %	123,562	0.2898 %	31 632 $
Ken Berlin 0.000636 %	271	0.000636 %	69 $
James P. Patton 0.000565 %	241	0.000565 %	62 $
Roni Appel 0.000312 %	133	0.000312 %	34 $
David Sidransky 0.000218 %	93	0.000218 %	24 $
Samir Khleif 0.000138 %	59	0.000138 %	15 $
Richard Berman 0.000110 %	47	0.000110 %	12 $

Ayala Pharmaceuticals, Inc.

9 Deer Park Drive Suite K-1

08852, Monmouth Junction

http://www.ayalapharma.com

address Ayala Pharmaceuticals, Inc.(ADXS)

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.171

Average target price

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
AYALA PHARMACEUTICALS, INC.	-74.36%	7.29M
MODERNA, INC.	+37.76%	52.5B
IQVIA HOLDINGS INC.	-7.47%	39.01B
LONZA GROUP AG	+37.72%	39.31B
ICON PUBLIC LIMITED COMPANY	+11.93%	26.2B
CELLTRION, INC.	-11.17%	26.57B
ALNYLAM PHARMACEUTICALS, INC.	+16.45%	28.2B
UNITED THERAPEUTICS CORPORATION	+45.05%	14.15B
MEDPACE HOLDINGS, INC.	+33.13%	12.62B
BIO-TECHNE CORPORATION	-3.46%	11.74B

Other Biotechnology & Medical Research